Ameriprise
IMUX icon

Ameriprise’s Immunic IMUX Stock Holding History

Ameriprise’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,590
Closed -$22K – 3987
2022
Q4 		$22K Sell
1,590
-1,272
-44% -$34.7K ﹤0.01% 3890
2022
Q3 		$90K Buy
2,862
+20
+0.7% +$837 ﹤0.01% 3842
2022
Q2 		$99K Buy
2,842
+819
+40% +$52.5K ﹤0.01% 3784
2022
Q1 		$228K Buy
2,023
+690
+52% +$79.9K ﹤0.01% 3727
2021
Q4 		$128K Sell
1,333
-954
-42% -$85.9K ﹤0.01% 3847
2021
Q3 		$202K Sell
2,287
-80
-3% -$7.87K ﹤0.01% 3703
2021
Q2 		$290K Buy
2,367
+199
+9% +$27.5K ﹤0.01% 3652
2021
Q1 		$345K Sell
2,168
-646
-23% -$110K ﹤0.01% 3548
2020
Q4 		$430K Buy
2,814
+1,122
+66% +$201K ﹤0.01% 3397
2020
Q3 		$314K Buy
+1,692
New +$277K ﹤0.01% 3408

Other funds holding IMUX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Ameriprise's IMUX Position: Q1 2023 in Review

Ameriprise sold out of Immunic (IMUX) in Q1 2023, closing a stake of 1,590 shares — an estimated $22K sold.

Ameriprise first reported a position in IMUX in Q3 2020 and held it in 10 quarters. The position peaked at $430K in Q4 2020. 59 funds tracked by Wall St. Rank hold IMUX as of Q1 2023.

  • Ameriprise reported no remaining Immunic position as of Q1 2023 after selling out during the quarter.
  • Ameriprise sold 1,590 Immunic shares in Q1 2023, an estimated $22K.
  • Ameriprise first reported a position in Immunic in Q3 2020 and held it in 10 quarters.
  • Ameriprise's Immunic position peaked at $430K in Q4 2020.
  • 59 funds tracked by Wall St. Rank held Immunic as of Q1 2023.

Based on Ameriprise's 13F filing for Q1 2023, filed 15 May 2023.